Infant / Children's Health

The microbiota during the first 1000 days of life

Kaneka Probiotics’ Baby Colic is a patented probiotic with clinically demonstrated effect in reduction of excessive crying due to infant colic. Its formulation contains two clinical strains and there have been two published clinical trials (randomized, double-blind, placebo controlled design).

Kaneka Probiotics’ Baby Colic formula contains two unique strains of Pediococcus pentosaceus and Bifidobacterium longum. Unique mechanism of action: promotes the positive microbiota (Bifidobacterium and Lactic Acid), Homofermentative metabolism strains selected for Baby Colic do not produce CO₂, efficacy demonstrated in breast-feeding and formula-feeding infants; reduced crying-time by more than 60% after only 2 weeks.

Floradapt Baby Colic

B. longum KABP 042
P. pentosaceus KABP 041

Drops

Infant colic.*
Supports healthier microflora balance, which is correlated with decreased crying time in colicky infants.*
Promotes beneficial gut microflora.*
Custom formulations available.*

Daily dose in final product:

1 billion CFU

Scientific support:

Santas JM, et al. Int J Pharm Bio Sci. 6, 458- 466 (2015).
Navarro-Tapia E, et al. Ann. Nutr. Metab. 74, 1–31 (2019).
Chen K, et al. The efficacy of 3 week’s daily supplementation with a two-combined probiotic strains on infant colic. Manuscript submitted.
Tintore M, et al. Probiotic treatment with AB-KOLICARE causes changes in the microbiota which correlate with a reduction in crying time. Int. J. pharma Bio Sci. 8, 281- 288 (2017).
Tintore M, et al. Arch. Clin. Microbiol. 08, 56 (2017).

document

Floradapt Digest

B. longum KABP 042
P. pentosaceus KABP 041
L. rhamnosus GG

Sticks

Drops

Shots

Additional compounds:

Inulin, Fructooligosaccharides (FOS), Zinc

Daily dose in final product:

6 billion CFU

Scientific support:

Szajewska H, et al. Aliment Pharmacol Ther. 38, 467–76 (2013).
Szajewska H, et al. Aliment Pharmacol Ther. 42, 1149–57 (2015).
Tintore M, et al. Probiotic treatment with AB-KOLICARE causes changes in the mi- crobiota which correlate with a reduction in crying time. Int. J. pharma Bio Sci. 8, 281-288 (2017).
Astó E, et al. Equivalence of a novel Lac- tobacillus rhamnosus isolate to the referen- ce ATCC53103 strain. Poster presented at SEPyP congress (2018).

document

New
products

G.I. and Gastrointestinal
health

Mood
& Stress

Cardiovascular
health

Infant / Children's
health

Want to know more about our products?

What our partners say

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

References

Koppen, IJ, et al. 2016 The pediatric Rome IV criteria: what’s new? Expert Rev Gastroenterol Hepatol 2017; 11(3): 193-201.
Ortega E, Barroso D. Cólico del lactante. Rev. Pediatr. Aten. Primaria Supl. 2013; (22):81-7. 2013;(22):81-7.
Akhnikh, S, et al. The Excessively Crying Infant: Etiology and Treatment. 2014. Pediatric Annals 43:4.
Pärtty A et al. Compositional development of Bifidobacterium and Lactobacillus microbiota is linked with crying and fussing in early infancy. PLoS One. 2012. 7(3):e32495.
De Weerth et al. Intestinal Microbiota of Infants with Colic: Development and Specific Signatures. Pediatrics 2013;131(2): e550.
Ellett ML et al. Out of the abyss of colic: a view through the fathers’ eyes. MCN Am J Matern Child Nurs. 2009;34(3):164-71.
Santas J, et al. Pediococcus pentosaceus CECT 8330 and Bidobacterium longum CECT 7894 show a trend towards lowering infantile excessive crying syndrome in a pilot clinical trial. Int J Pharm Bio Sci. 2015; 6(2): 458-466.
Tintoré M et al. Probiotic treatment with AB-Kolicare® causes changes in the microbiota which correlate with a reduction in crying time. Int J Pharm Bio Sci 2017 Jan; 8(1): (B) 281–288.
Garrison, MM; Christakis, DA. A systematic review of treatments for infant colic. 2000. Pediatrics 106: 184-190;
Crotteau, C. What is the best treatment for infants with colic? Clinical Inquiries. The Journal of Family Practice. 2006. Vol. 55, No. 7. 11. IPP AB-COLIC 2015;

*These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

The clinical outcomes contained herein are based on the findings of competent and reliable scientific studies on healthy individuals. The results are discussed herein for informational purposes only. This content is not to be construed as advice regarding advertising claims for consumer-packaged goods. Kaneka is not responsible for the structure function claims used in advertising and promotions of consumer-packaged goods that contain the ingredients discussed herein, and any customer or manufacturer should check the regulatory status of any claims intended to be used according to the intended use of their products.

Infant / Children's Health

The microbiota during the first 1000 days of life

Floradapt Baby Colic

B. longum KABP 042 P. pentosaceus KABP 041

Drops

Daily dose in final product:

Scientific support:

Floradapt Digest

B. longum KABP 042 P. pentosaceus KABP 041 L. rhamnosus GG

Sticks

Drops

Shots

Additional compounds:

Daily dose in final product:

Scientific support:

Want to know more about our products?

Want to know more about our products?

What our partners say

References

B. longum KABP 042
P. pentosaceus KABP 041

B. longum KABP 042
P. pentosaceus KABP 041
L. rhamnosus GG